MOUNTAIN VIEW, Calif., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM) today announced that Magistrate Judge Elizabeth D. Laporte of the U.S. District Court for the Northern District of California issued an Order granting Complete's Motion for Partial Summary Judgment of invalidity in the patent infringement lawsuit filed against Complete by Illumina, Inc. In that lawsuit, filed in August 2010, Illumina alleges that Complete infringes U.S. Patent No. 6,306,597. In her October 16, 2012 Order, Judge Laporte declared that Claim 1 and dependent Claims 9, 10, 14, 15, 16, 17, 18 and 19 of Illumina's '597 patent are all invalid due to prior art. "We are very pleased that the Court agreed with the position we have maintained from the commencement of this litigation, that the primary claims in Illumina's '597 patent are invalid," said Dr. Clifford Reid, Complete's Chairman, President and Chief Executive Officer. Illumina's only remaining allegation in the lawsuit is that Complete infringes Claims 2, 4 and 5 of the '597 patent. Given the Court's prior claim construction order, Complete strongly believes that it does not infringe these Claims and intends to continue to vigorously defend itself. About Complete Genomics Through its pioneering sequencing-as-a-service model, Complete Genomics provides the most accurate whole human genomes available today. The ease of use and power of Complete's advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Additional information can be found at http://www.completegenomics.com. Caution Regarding Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the remaining claims in this litigation. These forward-looking statements are based on management's current expectations, are not guarantees of future performance, and involve certain risks and uncertainties that could cause actual results to differ materially from management's current expectations and these forward looking statements. These risk and uncertainties include, but are not limited to, the unpredictable nature of litigation, as well as other risks detailed in our most recent Annual Report on Form 10-K (filed with the SEC on March 9, 2012) and our most recent Quarterly Report on Form 10-Q (filed with the SEC on August 9, 2012). We disclaim any obligation to update information contained in our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Complete Genomics, Inc. Scott Sandler Investor Relations (650) 943-2788 firstname.lastname@example.org